Differences in the effectiveness of sympathetic radiofrequency denervation of the renal arteries in patients with resistant arterial hypertension and hyperuricemia

Objective. To evaluate of differences in the effectiveness of sympathetic radiofrequency denervation (RDN) of renal arteries (RA) in patients with resistant arterial hypertension (RAH) with hyperuricemia (HUA) during 3 years of follow-up. Design and methods. The study included 80 patients with RAH, who were randomized to RDN RA group with medication therapy (MT) and MT group. Groups were comparable in age, gender, duration of hypertension and the number of antihypertensive medications. In 12 months, comparative study was completed, and RDN RA group of patients was examined in 24 and 36 months, results were analyzed depending on the initial level of uric acid (UA). Results. In RDN RA group, compared with MT group, beneficial antihypertensive effect was found both in terms of office blood pressure (BP) and ambulatory BP monitoring (ABPM). After RDN RA, significant decrease in BP persisted for 3 years. Analysis of antihypertensive effect of interventional treatment depending on UA level showed significant decrease in office BP and all indicators of ABPM in patients with normal levels of UA. In HUA patients, only decrease in office BP and mean daily systolic BP was revealed. The majority of patients with favorable response to RDN (“responders” group) showed normal UA (75 % vs. 83,3 %, respectively, at 24, 36 months of follow-up). The creatinine and cystatin C levels in dynamics were slightly increased, but within reference ranges. Conclusions. Obtained data indicated more pronounced clinical efficacy of RDN RA in patients without HUA.

1. Boytsov SA, Balanova YA, Shalnova SA, Deev AD, Artamonova GV, Gatagonova TM et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from eccd. Cardiovasc Ther Prev. 2014;13(4):4-14. doi:10.15829/1728-8800-2014-4-4-14. In Russian.

2. Lewington S, Clarke R, Qizibash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality. Lancet. 2002;360(9349):1903-1913.

3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339

4. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.

5. Siddiqui M, Dudenbostel T, Calhoun DA, Siddiqui M. Resistant and refractory hypertension: antihypertensive treatment resistance vs treatment failure. Can J Cardiol. 2016;32(5):603-606. doi:10.1016/j.cjca.2015.06.033

6. Chazova IE, Danilov NM, Litvin AIu. Resistant arterial hypertension. Monografiia. M.: Atmosfera, 2014; P. 256. In Russian.

7. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012;380(9841):591-600. doi:10.1016/S0140-6736(12)60825-3

8. Lobo M, de Belder M, Cleveland T, Collier D, Dasgupta I, Deanfield J et al. Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension. Heart. 2015;101(1):10-16. doi:10.1136/heartjnl-2014-307029

9. Zvartau NE, Konradi AO. Update on interventional approaches to treatment of hypertension. Arterial'naya Gipertenziya = Arterial Hypertension. 2015;21(5):450-458. doi:10.18705/1607-419Х-2015-21-5-450-458. In Russian.

10. Ripp TM, Mordovin VF, Pekars-kiy SE, Ryabova TR, Zlobina MV, Krilov AL et al. Sympathetic denervation of the renal arteries for the treatment of resistant hypertension — safety control by ultrasound diagnostics. Arterial'naya Gipertenziya = Arterial Hypertension. 2013;19(2):2-8. In Russian.

11. Krum H, Schlaich M, Whitboumet R, Sobotka P, Sadowsk J, Bartus K et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;30(373):1275-1281. doi:10.1016S01406736(09)60566-3

12. Danilov NM, Matchin YuG, Chazova IE. Endovascular radio-frequency denervation of renal arteries as an innovation method of treatment of refractory arterial hypertension. The first experience in Russia. Angiology and Vascular Surgery. 2012;18(1):51-54. In Russian.

13. Mahfoud F, Bohm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40(42):3474-3482. doi:10.1093/eurheartj/ehz118

14. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108)2160-2170. doi:10.1016/S0140-6736(17)32281-X

15. Mahfoud F, Bohm M, Edelman E. Catheter-based renal denervation in hypertension: heading for new shores. J Hypertens. 2018;36(1):41-42. doi:10.1097/HJH.0000000000001614

16. Zvartau NE, Zverev DA, Konradi AO. Renal denervation in resistant hypertension — to be or not to be? Arterial'naya Gipertenziya = Arterial Hypertension. 2014;20(2):155-156. doi:10.18705/1607-419x-2014-20-2-125-126. In Russian.

17. Grigin VA, Danilov NM, Matchin YuG, Shchelkova GV, Chazova IE. Radiofrequency denervation of the renal arteries: waiting for answers. Sistemniye Gipertenzii = Systemic Hypertension. 2015;1:8-9. doi:10.26442/SG29083. In Russian.

18. Mahfoud F, Bakris G, Bhatt DL, Esler M, Ewen S, Fahy M et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J. 2017;38(2):93-100. doi:10.1093/eurheartj/ehx215

19. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-1401. doi:10.1056/NEJMoa1402670

20. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64(11):1071-1078. doi:10.1016/j.jacc.2014.05.012

21. Epstein M, de Marchena E. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the “end of the road” for renal denervation? J Am Soc Hypertenses. 2015;9(2):140-149. doi:10.1016/j.jash.2014.12.002

22. Blankestijn P, Bots M. Device therapy for uncontrolled hypertension: new approaches to an old problem. Nat Rev Nephrol. 2017;13(12):725-726. doi:10.1038/nrneph.2017.150

23. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160-2170. doi:10.1016/S0140-6736(17)32281-X

24. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335-2345. doi:10.1016/S0140-6736(18)31082

25. Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-2355. doi:10.1016/S0140-6736(18)30951-6

26. Pekarskiy SE, Baev AE, Mordovin VF, Semke GV, Ripp TM, Falkovskaya AU et al. Denervation of the distal renal arterial branches vs. conventional main renal artery treatment: a randomized controlled trial for treatment of resistant hypertension. J Hypertens. 2017;35(2):369-375. doi:10.1097/HJH.0000000000001160

27. Pekarskiy SE, Baev AE, Mordovin VF, Popov SV. The treatment of hypertension by renal denervation: an effective optimization of the therapy. Tomsk, Milon Company LLC, 2017, 222 p. In Russian.

28. Silverwatch J, Marti KE, Phan, Amin H, Roman YM, Pasupuleti V et al. Renal denervation for uncontrolled and resistant hypertension: systematic review and network meta-analysis of randomized trials. J Clin Med. 2021;10(4):782. doi:10.3390/jcm10040782

29. Danilov NM, Agaeva RA, Matchin UG, Grigin VA, Shchelkova GV, Ripp TM et al. Russian Medical Society on Arterial Hypertension (RMSAH) Consensus of Experts on the use of radiofrequency denervation of the renal arteries in patients with arterial hypertension. Sistemniye Gipertenzii = Systemic Hypertension. 2020;17(4):7-18. doi:10.26442/2075082X.2020.4.200398. In Russian.

30. Schmieder RE, Mahfoud F, Mancia G, Azizi M, Bohm M, Dimitriadis K, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733-1741. doi:10.1097/HJH.0000000000002933

31. Pekarskiy S, Baev A, Mordovin V, Ripp T, Falkovskaya A, Lichikaki V, Sitkova E. First-in-man experience of distal renal denervation in segmental branches of renal artery using multielectrode balloon device. J Hypertens. 2018;6(36):e167. doi:10.1097/01.hjh.0000539455.58879.3

32. Vel'kov VV. Cystatin C and NGAL — the markers of preclinical renal dysfuction and subclinical acute kidney injury. Laboratory Service. 2015;4(2):38-43. doi:10.17116/labs20154238-43. In Russian.

33. Mironova SA, Yudina YuS, Ionov MV, Avdonina NG, Emelyanov IV, Vasil'eva EYu et al. Biomarkers of kidney injury in hypertension: conventional versus novel. Arterial'naya Gipertenziya = Arterial Hypertension. 2018;24(2):223-236. doi:10.18705/1607-419X-2018-24-2-223-236. In Russian.

34. Ruda MM, Karpov Yu A. Hyperuricemia and cardiovascular risk: a modern view of the problem. Atmosphere. Cardiology News. 2020;1:3-14. doi:10.24411/2076-4189-2020-12201. In Russian.

35. Stewart DJ, Langlois V, Noone D. Hyperuricemia and hypertension: links and risks. Integrated blood pressure control. Integr Blood Press Control. 2019;12:43-62. doi:10.2147/IBPC.S184685

36. Borghi C, Agabiti Rosei E, Bardin T, Dawson J, Dominiczak A, Kielstein JT. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-1741. doi:10.1097/HJH.0000000000000701

37. H0ieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041-1049. doi:10.1111/j.1523-1755.2004.00484.x

38. Chazova IE, Zhernakova JuV, Kisliak OA, Nedogoda SV, Podzolkov VI, Oshchepkova EV et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Sistemniye Gipertenzii = Systemic Hypertension. 2019;16(4):8-21. doi:10.26442/2075082X.2019.4.190686. In Russian.

39. Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Adv Exp Med Biol. 2017;956:307-325. doi:10.1007/5584_2016_84

40. Kobalava JD, Tolkacheva VV, Karaulova JL. Uric acid — a marker and/or a new risk factor for cardiovascular complications? Russian Journal of Medicine. 2002;10:431-436. In Russian.

41. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PUIMA study. Hypertension. 2000;36(6):1072-1078. doi:10.1161/01.hyp.36.6.1072

42. Shcherbak AV, Kozlovskaia LV, Bobkova IN, Balkarov IM, Lebedeva MV, Stakhova TIu. Hyperuricemia and the problem of chronic kidney disease. Terapevticheskii Arkhiv = Ter Arkh. 2013;85(6):100 104. In Russian.

43. Mukhin NA, Fomin VV, Lebedeva MV. Hyperuricemia as a component of cardiorenal syndrome. Terapevticheskiy Arkhiv = Ter Arkh. 2011;83(6):5-13. In Russian.

44. Stakhova TYu, Pulin AA, Severova MM et al. Clinical implication of endothelial dysfunction in patients with essential arterial hypertension and urate dysbolism with renal damage. Terapevticheskiy Arkhiv = Ter Arkh. 2011;83(10):36-40. In Russian.

45. Shalnova SA, Deev AD, Artamonov GV, Duplyakov DV, Efanov AYu, Zhernakova YuV et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):153-159. doi:10.20996/1819-6446-2014-10-2-153-159. In Russian.

46. Molchanova OV, Britov AN, Platonova EV. Importance of elevated uric acid levels in the development and prevention of chronic non-communicable diseases. Profilakticheskaya Meditsina = Preventive Medicine. 2020;23(2):102-108. doi:10.17116/profmed202023021102. In Russian.

47. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99(11):759-766. doi:10.1136/heartjnl-2012-302535

48. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6): 1183-1190. doi:10.1161/01.HYP.0000069700.62727.C5

49. Kenney MJ, Ganta CK. Autonomic nervous system and immune system interaction. Compr Physiol. 2014;4(3):1177-1200. doi:10.1002/cphy.c130051

50. Chobanyan-Jurgens K, Jordan J. Autonomic nervous system activity and inflammation: good ideas, good treatments, or both? Am J Physiol. 2015;309(12): H1999-H2001. doi:10.1152/ajpheart.00826.2015

51. Shchelkova GV, Zairova AR, Danilov NM, Rogoza AN, Chazova IE. The local arterial stiffness and vasomotor endothelial function in patients with resistant hypertension and effect of renal denervation on them. Kardiologicheskij Vestnik = Cardiology Bulletin. 2017;2:10-17. In Russian.

52. Zaldivia MTK, Rivera J, Hering D, Marusic P, Sata Y, Lim B et al. Renal denervation reduces monocyte activation and monocyte-platelet aggregate formation: an anti-inflammatory effect relevant for cardiovascular risk. Hypertension. 2017;69(2):323-331. doi:10.1161/HYPERTENSIONAHA.116.08373